Isolation and Identification of 2-Oxo-5-guanidinovaleric Acid in Urine of Patients with Hyperargininaemia by Chromatography and Gas Chromatography/Mass Spectrometry by Marescau, B. et al.
Marescau et al.t 2-Oxo-5-guanidinovaleric acid in hyperaigininaemia urine 61
J. Clin. Chem. Clin. Biochem.
Vol. 19,1981, pp. 61-65
Isolation and Identification of 2-Oxo-5-guanidinovaleric Acid in Urine of Patients with Hyperar-
gininaemia by Chromatography and Gas Chromatography/Mass Spectrometry
By B. Marescau, J. Pintens, A. Lowenthal
Department of Neurochemistry, Born-Bunge Foundation, Universitaire Instelling Antwerpen, Wilrifk, Belgium,
E. Esmans, Y. Luyten, G. Lemiere, R. Dommisse, F. Alderweireldt
University of Antwerp fRUCA), Laboratory for Organic Chemistry, Antwerpen, Belgium, and
H. G. Terheggen
Children's Hospital, Neuss, Federal Republic of Germany
(Received March 6/August 25,1980)
Summary: An unknown guanidino-positive compound peak has been identified in urines of three sisters affected
with hyperargininaemia. Identification was made on the basis of its similarity with the liquid and thin-layer Chro-
matographie characteristics of enzymatically synthesized 2-oxo-5-guanidinovaleric acid. Identification was also made
by combined gas chromatography — mass Spectrometry of the unknown compound peak. The synthesis of enzyma-
tically formed 2-oxo-5-guanidinovaleric acid was controlled by nuclear magnetic resonance and combined gas chro-
matography — mass Spectrometry.
Isolierung und Identifizierung von 2-Oxo-5-guanidinovaleriansäure im Harn von Patienten mit Hyperargininämie
durch Chromatographie und Gaschromatographie/Massenspektrometrie
Zusammenfassung: Eine unbekannte Guanidin-positive Verbindung im Harn dreier Schwestern mit Hyperarginin-
ämie wurde identifiziert. Die Identifizierung erfolgte aufgrund der Ähnlichkeit des flüssig- und dünnschicht-chro-
matographischen Verhaltens von enzymatisch synthetisierter 2-Oxo-5-guanidinovaleriansäure sowie kombinierter
Gaschromatographie/Massenspektiometrie der unbekannten Substanz. Die Synthese der enzymatisch hergestellten
2-Öxo-5-guanidinovaleriansäure wurde mit Kernresonanzspektrometrie und kombinierter Gaschromatographie/
Massenspektrometrie kontrolliert.
Introduction Figure l gives the different monosubstituted guanidino
An unknown guanidino-positive compound peak was compounds in parallel with the amino acids, in urine of
previously shown by liquid chromatography in the urine the patients. The concentrations of the guanidino com-
of three sisters affected with hyperargininaemia. This pounds in patients with hyperargininaemia are ten to
compound peak was named compound X as shown in hundred times higher than in controls, except for guani-
the previous publications (1—3). This peak, having more dinosuccinic acid. There is much controversy about the
than one shoulder, appears complex and is Sakaguchi biosynthesis of guanidinosuccinic acid (5, 6).
and -naphthol positive. This peak is unstable and can
degrade to 4-guanidinobutyric acid. By using the same The neurological disturbances in the patients with hyper-
color factor as the nearest eluted guanidino compounds, argininaemia could be caused by hyperammonaemia,
concentration values up to 5000 /g creatinine were but the high guanidino levels could also play a patholo-
found. Only traces are found in the urines of controls. gical role. Indeed, some guanidino compounds have con-
In our preliminary study, this unknown compound peak vulsive effects on rabbits and cats when administered in-
was identified as 2-oxo-5-guanidinovaleric acid (4). tracisternally (7).
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Fig. 1. Elution pattern of urinary mono substituted guanidino compounds, in parallel with amino acids, of patients with hyperargini-
nemia.
? = unknown monosubstituted guanidino compounds.
I. urea, 2. aspartic acid, 3. threonine, 4. serine, 5. glutamine, 6. glutamic acid, 7. citrulline, 8. glycine, 9. alanine, 10. cystine,
II. methionine, 12; isoleucine, 13. leucine, 14. tyrosine, 15. 3-aminoisobutyric acid, 16. ethanolamine, 17. ammonia, 18. orni-
thine, 19. lysine, 20. histidine, 21. arginine.
Materials and Methods
Materials
Apparatus
Liquid chromatography was performed on a Technicon AAI
amino acid analyzer (Technicon Instruments, Tarrytown NY
10591). The column, length 140 cm, internal diameter 6.2 mm,
was filled to 130 cm with Dowex 50 X 8 (resin Technicon Chro-
mobeads® type A, particle size 21 ìðé). The operating flow rate
was 0.5 mi/min.
The GC-MS apparatus was a Ribermag RIO-ÉÏ, fitted with a
2.5 m 3% SE 30 on chromosorb W column, (NERMAG, 92502,
Rueil-Malmaison, Paris, France). Nuclear magnetic resonance
spectra were determined with a Jeol JNM-PS 100 spectrometer
operating at 100 MHz for protons (Jeol LTD 1418 Nakagami
Akishima, Tokyo 196)
For desalting the unknown peak a jacketed Econo-column with
nylon 3-way Luer Stopcocks, measuring 50 X 1.5 cm was used,
(Bio-Rad, Richmond, California).
Reagents
For liquid chromatography, all the reagents were pro analysis.
The resin used for desalting was Dowex 50W-X8 (H+) (50 to 100
mesh) and obtained from Fluka (Fluka AG, CH-9470 Buchs,
Switzerland). The silylating agents were obtained from Pierce
(Pierce Chemical Company, Rockford 1L 61105). The dimethyl-
pyrimidyl forming agent was acetylacetone, Merck (E. Merck,
Darmstadt, West-Germany).
Specimens
The urines of the three patients, received through the care of
one of us (Prof. Dr. //. G. Terheggen) were studied.
Methods
Enzymatic synthesis of 2-oxo-5-guanidinovaleric acid
2-Oxo-5-guanidinovaleric acid was synthesized according to the
method described by Cooper et al. (8) with minor modifications.
The enzymatic synthesis of 2-oxo-5-guanidinovaleric acid was
controlled by nuclear magnetic resonance and GC-MS studies.
Nuclear magnetic resonance control of the enzymaticatty synthe-
sized 2-oxo~5-guanidinovaleric acid
An aliquot was dissolved in D2O and the spectra were run at
100 MHz.
Desalting of the urine fraction corresponding with the unknown
guanidino-positive compound peak
The eluent from the AAI analyzer, containing the unknown
guanidino positive peak, was collected and desalted on the
jacketed Econo-column of Dowex 50 W-X8 (H+) (50*10 100
mesh). The jacket temperature was 3 °C. After applying the salt
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solution, the column was washed with distilled water. The elu-
tion was carried out with NH4OH (0.3 mol/1) long enough for
the eluent to become basic. After this, the column was washed
with a final volume of water. For a resin height of 25 cm, the
first washing volume was 250 ml, the elution volume 250 ml and
the final volume 75 ml. The used flow rate was 0.5 ml/min. Am?
monia was removed as soon as possible from the eluent with a
rotavapor. Then the eluent was lyophilised and an aliquot was
used for thin-layer chromatography and for GC-MS studies.
Liquid ion-exchange chromatography
NH2
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61 CH2É ÷
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Free mo no substituted guanidino compounds were analysed in
parallel with amino adds as described byDurzan (9). The elu-
tion procedure for liquid ion-ex can ge chromatography was ac-
cording to Efron (10).
Thin-layer chromatography
One dimensional thin-layer chromatography was performed in
a chamber saturated with solvent by means of filter paper lining.
Different solvents were used, e.g. n-propanol/acetic acid 1 mol/1
(150ml+ 50 ml).
After chromatography, the plates were dried at room tempera-
ture. To locate the guanidino compounds, the plates were
sprayed with Sakaguchi reagent prepared according to Jepson et
al. (11). Orange to red spots appeared.
Derivatization and GC-MS conditions
For GC-MS studies the guanidino compounds were converted to
dimethylpyrimidyl derivatives by a method described by Mori
et al. (12): aliquots of about 5 mg of enzymatically synthesized
2-oxo-5-guanidinovaleric acid and the desalted urine fraction
were used. The dimethylpyrimidyl derivatives were silylated with
0.5 ml pyridine, 0.2 ml hexamethyldisilazane and 0.1 ml trime-
thylchlorosilane. The silylation occurred at room temperature. A
helium flow of 20 ml/min was used. After injection of an aliquot
of 1 ìÀ, the oven was programmed from 80 °C up to 220 °C at
8 °C/min.
The mass spectral conditions were: source temperature 140 °C;
ionisatioç voltage: 80 eV; emission current: 200 ìÁ; integration
time : 6 ms.
COOH
2-Oxo-S-guonidinovaleric acid Pyrroljdine-l-amidino-2-hydroxy-
2-carboxylJc acid
Fig. 2. Structures of 2-oxo-5-guanidinovaleric acid and its cyclic
form.
Tab. 1. Chemical shift ä-values in ppm relative to internal DSS of
2-oxo-5-guanidinovaleric acid and its cyclic form.
ä-values
Tl 2.75 (triplet)
7! 1.79 (pentuplet)
61 3.13 (triplet)
02 + 72 1.55-2.6 (broad band)
62 3.2 -3.8 (multiplet)
6-Guqnidino-
coproic odd
Results
The proton nuclear magnetic resonance studies have con-
firmed the findings of Cooper et al. (8) that 2-oxo-5-gua-
nidinovaleric acid exists in equilibrium with its cyclic
form. We have found 23% open and 77% closed form.
Figure 2 gives the structure, and table 1 gives the
chemical shift ä-values in ppm relative to internal DSS.
The shape and elution time of the unknown guanidino-
positive compound peak were the same as those of enzy-
matically synthesized 2-oxo-5-guanidinpvaleric acid. One
and the same compound peak was observed by chroma-
tography of hyperargimnaenua urine together with the
enzymatically synthesized 2-oxo.5-guanidinovaleric acid.
The presence of more shoulders could be caused by mo-
difications of the equilibrium during the elution. The
elution time was the same as those of citrulline, glycine
and alanine.
The Rp value of enzymatically synthesized 2-oxo-5-gu-
anidinovaleric acid was the same as those of the unknown
guanidino positive urine peak. One and the same spot
was observed by chromatography of a mixture of both
fractions. Figure 3 gives the TLC results in /i-propanol/
4-Guonidino-
butyric acid
2-Oxo-S -guonidino-
voleric acid
* *
Arginine
Start
Fig. 3. Thin layer chromatography of
1 standard of arginine and 4-guanidinobutyric acid,
2 unknown peak and 6-guanidinocaproic acid as internal
standard,
3 standard of 2-oxo-5-guanidinovaleric acid and 6-guani-
dinocaproic acid as internal standard,
4 mixture of unknown peak and standard of 2-oxo-5-gua-
nidinovaleric acid;
solvent: /z-propanol/ acetic acid (1 mol/1) (150 ml +
50ml).
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Fig. 4. Mass spectrum of the silylated dimethylpyrimidyl derivative of 2-oxo-5-guanidinovaleric acid.
acetic acid 1 mol/1 (150 ml + 50 ml). The first spot is a
standard of 4-guanidinobutyric acid and arginine. The
second spot is the unknown guanidino-positive compound
peak, with 6-guanidinocaproic acid added as internal
standard. The third spot is enzymatically synthesized
2-oxo-5-guanidinovaleric acid, with 6-guanidinocaproic
acid added as internal standard. The fourth spot is a mix-
ture of the urine fraction and enzymatically synthesized
2-oxo-5-guanidinovaleric acid. 2-Oxo-5-guanidinovaleric
acid degrades to 4-guanidinobutyric acid (fig. 3) in
an aqueous medium enriched with oxygen. This is a
chemical degradation (13).
Since compounds containing a guanidino function are
not suitable for GC-MS analysis, both enzymatically syn-
thesized 2-oxo-5-guanidinovaleric acid and the unknown
urine peak were converted into the silylated dimethyl-
pyrimidyl derivative.
The mass spectrum of this derivative is depicted in figure
4. The same fragment ions were observed for both the
enzymatically synthesized product and the unknown
urine peak.
No signal at m/z = 309 was observed because of the ease
of water elimination from the cyclic form during the deri-
vatisation procedure. The molecular ion (M)+ at m/z =
291 was due to the dehydrated cyclic silylated dimethyl-
pyrimidyl compound. Typical fragment ions are m/z =
276, 202, 174, 107 and 73 of which the origin is shown
in figure 4.
Ion m/z = 200 (base peak) can be explained by the eli-
mination of (CH3)3 SiOH from the (M-H)+ -fragment ion
(m/z = 290). Loss of a (CH3)3 SiOCO-radical from the
(Ì-Ç)+-ßïç leads to m/z = 173.
Discussion
Only eight patients with hyperargininaemia, from five
different families, have been described (14-18). The
first clinical symptoms such as irritability, coma and con-
vulsions were the same as those of the other hyperam-
monaemias. The development of the patients is characte-
rised by neurological degradation, resulting in spasticity,
athetosis and ataxia. They are also mentally retarded.
Hepatomegaly and an increase of the activity of trans-
aminases and aldolases was also seen in our patients.
Different problems arise in these patients:
a) In view of the neurological picture of the patients, the
main question is: is there a correlation between the
neurological symptoms and the elevated arginine and
guanidino compounds in the biological fluids?
b) In the biochemistry of these patients, there are several
interesting points like the normal or low normal va-
lues of blood urea, in contrast with arginase deficiency.
Three possibilities for this anomaly have been sugges-
ted:
S f
1. that the enzyme defect is only partial (19);
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2. that the urea-cycle enzymes in different organs are
under different genetic controls and that the bio-
chemical defect involves one or more, but not all,
organs (20);
3. that there is an alternative pathway for urea pro-
duction (21).
c) Metabolism of guanidino compounds:
1. The patients with hyperargininaemia try to meta-
bolize their high arginine load. Therefore elevated
levels of guanidino compounds were to be expected.
As can be seen in table 2, the excretion values of
the monosubstituted guanidino compounds are ten
to hundred times higher than those of controls, ex-
cept for guanidinosuccinic acid. The excretion va-
lue of guanidinosuccinic acid is even lower than in
controls. Guanidinosuccinic acid does not seem to
be synthesized from arginine.
2. Little is known about the synthesis of guanidino
compounds in vivo. Guanidinoacetic acid is formed
by a transamidination reaction: the amidino group
of arginine is transferred to glycine (22). Guanidi-
noacetic acid is an intermediate in the biosynthesis
of creatine and creatinine. 4-Guanidinobutyric acid
can also be formed by transamidination from argi-
nine to 4-aminobutyric acid (23). N-a-acetylargi-
nine could be formed by an acetylation of arginine.
And deammation of arginine, followed by an hydro-
genation could give argininic acid.
Patients with hyperargininaemia are characterised by an
abnormal metabolism of the guanidino compounds. In
Tab. 2. Excretion values of some monosubstituted guanidino
compounds in urine.
Controls Patient 1 Patient 2 Patient 3
ìçéïÀ/g cratinine
Guanidinoacetic acid 418
Guanidinosuccinic acid 63
N-o-acetylarginine 33
Arginicacid 14
4-Guanidinobutyric
acid 9 123
2-Oxo-5-guanidino-
745 2764 1182
traces traces traces
734 4271 649
355 1069 61
valeric acid traces 2228
233
6410
19
904
this work we have demonstrated that the liquid and thin-
layer chromographic characteristics and the mass spec-
tral data of the unknown guanidino positive peak in the
urines of the three patients with hyperargininaemia were
identical with the results obtained with the enzymatical-
ly synthesized 2-oxo-5-guanidinovaleric acid. Therefore
we can conclude that 2-oxo-5-guanidinovaleric acid is
present in the urine of the three patients with hyperar-
gininaemia.
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